文献速递胸部CT

影像组学用于临床及病理IA期纯实性非小细胞肺癌的生存风险分层

Radiomics for Survival Risk Stratification of Clinical and Pathologic Stage IA Pure-Solid Non-Small Cell Lung Cancer.
PubMed 文献 · Radiology · 2021-11-02

该回顾性研究构建了6种影像组学特征,用于临床及病理IA期纯实性非小细胞肺癌患者的生存风险分层,在内部验证集和外部验证集分别评估。联合三区域特征的影像组学特征获得最高3年和5年AUC,内部验证集分别为0.77和0.78,外部验证集分别为0.76和0.75,多变量分析提示该特征是独立预后因素(HR 6.2)。

要点

  • 联合瘤内二维、三维及瘤周区域特征的影像组学特征具有最高判别能力。
  • 内部验证集3年、5年AUC分别为0.77、0.78,外部验证集分别为0.76、0.75。
  • 多变量分析提示影像组学特征是独立预后因素(HR 6.2,95%CI 3.5~11.0,P<.001)。

核心结论

  • 联合多区域特征的影像组学特征有助于对临床及病理IA期纯实性非小细胞肺癌患者进行生存风险分层。

研究设计与样本

  • 回顾性研究,共纳入592例IA期纯实性非小细胞肺癌患者(中位年龄61岁,四分位距55~66岁,女性269例),其中训练集381例、内部验证集163例、外部验证集48例;于2011年1月至2013年12月在作者所在机构接受切除术,影像组学特征采用PyRadiomics从瘤内二维区域、三维体积及瘤周区域提取。

诊断标准与关键数值

  • 联合三区域特征的影像组学特征在内部验证集的3年和5年AUC分别为0.77和0.78,在外部验证集的3年和5年AUC分别为0.76和0.75;多变量分析显示该特征为独立预后因素(HR 6.2,95%CI 3.5~11.0,P<.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Radiomics-based biomarkers enable the prognostication of resected non-small cell lung cancer (NSCLC), but their effectiveness in clinical stage and pathologic stage IA pure-solid tumors requires further determination. Purpose To construct an efficient radiomics signature for survival risk stratification personalized for patients with clinical stage and pathologic stage IA pure-solid NSCLC. Materials and Methods In this retrospective study, six radiomics signatures were constructed for patients with stage IA pure-solid NSCLC who underwent resection between January 2011 and December 2013 at authors' institution and were tested in the radiogenomics data set. The radiomics features were extracted from the intratumoral two-dimensional region, three-dimensional volume, and peritumoral area using PyRadiomics. The discriminative abilities of the signatures were quantified using the area under the time-dependent receiver operating characteristic curve (AUC), and the optimal signature was selected for patient stratification. Results The study included 592 patients with stage IA pure-solid NSCLC (median age, 61 years; interquartile range, 55-66 years; 269 women) for radiomics analysis: 381 patients for training, 163 for internal validation, and 48 for external validation. The radiomics signature combining three-region features yielded the highest 3- and 5-year AUCs of 0.77 and 0.78, respectively, in the internal validation set and 0.76 and 0.75, respectively, in the external validation set. Multivariable analysis suggested that the radiomics signature remained an independent prognostic factor (hazard ratio, 6.2; 95% CI: 3.5, 11.0; P < .001) and improved the discriminative ability and clinical usefulness of conventional clinical predictors. Conclusion The radiomics signature with multiregional features helped stratify the survival risk of patients with clinical stage and pathologic stage IA pure-solid non-small cell lung cancer. Published under a CC BY 4.0 license. Online supplemental material is available for this article. See also the editorial by Hsu and Sohn in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Wang, She, Yang, et al. Radiomics for Survival Risk Stratification of Clinical and Pathologic Stage IA Pure-Solid Non-Small Cell Lung Cancer. Radiology. 2021. PMID: 34726531. doi:10.1148/radiol.2021210109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。